NVO R&D Expenses

Novo Nordisk A/S Common Stock · R&D Expenses

NVO logo

NVO R&D Expenses

Latest reportedkr 58.11B DKK
NVO TTM R&D Expenses · DKK (kr 0.00 → kr 58.11B)
High-resolution chart · PNG

NVO r&d expenses history

Trailing twelve months (TTM) · DKK. Each value covers four complete reported quarters.

Novo Nordisk A/S Common Stock R&D Expenses — Trailing twelve months (TTM) (DKK)
Period endingR&D Expenses (DKK)
58,112,000,000
52,015,000,000
52,039,000,000
51,193,000,000
45,288,000,000
49,764,000,000
48,062,000,000
44,720,000,000
43,360,000,000
34,321,000,000
32,443,000,000
30,068,000,000
27,573,000,000
25,569,000,000
24,047,000,000
21,594,000,000
20,213,000,000
19,034,000,000
17,772,000,000
16,623,000,000
16,282,000,000
15,629,000,000
15,462,000,000
15,363,000,000
15,053,000,000
15,319,000,000
14,220,000,000
14,380,000,000
14,423,000,000
14,162,000,000
14,805,000,000
14,244,000,000
13,928,000,000
14,046,000,000
14,014,000,000
14,501,000,000
14,631,000,000
14,548,000,000
14,563,000,000
14,127,000,000
13,958,000,000
13,662,000,000
13,608,000,000
13,439,000,000
13,804,000,000
13,844,000,000
13,762,000,000
13,463,000,000
12,604,000,000
12,244,000,000
11,733,000,000
11,377,000,000
11,199,000,000
11,047,000,000
10,897,000,000
10,439,000,000
10,085,000,000
9,845,000,000
9,628,000,000
9,611,000,000
9,650,000,000
9,761,000,000
9,602,000,000
9,254,000,000
8,836,000,000
8,251,000,000
7,864,000,000
7,939,175,000
7,634,175,000
7,766,202,000
7,880,202,000
8,844,773,900
8,989,396,900
8,763,140,900
8,551,529,900
7,036,528,000
6,801,054,000
6,546,546,000
6,322,228,000
5,955,623,000
5,695,688,000
5,389,388,000
5,076,548,000
4,828,223,000
4,683,184,000
4,470,273,000
4,388,180,000
4,256,924,000
4,224,758,000
4,244,594,000
4,189,461,000
3,023,902,000
1,972,893,000
972,005,000
0
0
0
0
0
0
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.